Last reviewed · How we verify

Racemic Carazolol (CARAZOLOL)

Phase 2 active Small molecule

Racemic Carazolol (generic name: CARAZOLOL) is a carazolol drug. It is currently in Phase 2 development.

Carazolol works by selectively binding to and blocking the beta-2 adrenergic receptor, which is involved in various physiological responses.

Racemic Carazolol, also known as CARAZOLOL, is a small molecule drug that targets the beta-2 adrenergic receptor. It belongs to the carazolol drug class and was originally developed by an unknown entity. The commercial status of CARAZOLOL is unclear, and it is not FDA-approved for any indications. Further information on its pharmacokinetics and safety profile is also unavailable. As a result, CARAZOLOL is not widely recognized in the pharmaceutical industry.

Likelihood of approval
13.3% vs 15.3% industry baseline
If approved by FDA: likely 2031–2034
Steps remaining: Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 2 → approval rate +15.3pp
    Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
  • Cardiovascular Phase 3 risk -2.0pp
    Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2031–2034 —
EMA EU 2032–2035 +0.7 yr
MHRA GB 2032–2035 +0.7 yr
Health Canada CA 2032–2036 +0.9 yr
TGA AU 2032–2036 +1.2 yr
PMDA JP 2032–2036 +1.5 yr
NMPA CN 2033–2037 +2.3 yr
MFDS KR 2032–2036 +1.4 yr
CDSCO IN 2032–2037 +1.8 yr
ANVISA BR 2033–2037 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameCARAZOLOL
Drug classcarazolol
TargetBeta-2 adrenergic receptor, Beta-3 adrenergic receptor, Beta-1 adrenergic receptor
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 2

Mechanism of action

Imagine your body has a system of 'volume controls' that regulate how fast your heart beats and how much air you breathe. Carazolol is like a 'mute button' that turns down the volume on these controls, helping to slow down your heart rate and reduce airway constriction.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Racemic Carazolol

What is Racemic Carazolol?

Racemic Carazolol (CARAZOLOL) is a carazolol drug.

How does Racemic Carazolol work?

Carazolol works by selectively binding to and blocking the beta-2 adrenergic receptor, which is involved in various physiological responses.

What is the generic name of Racemic Carazolol?

CARAZOLOL is the generic (nonproprietary) name of Racemic Carazolol.

What drug class is Racemic Carazolol in?

Racemic Carazolol belongs to the carazolol class. See all carazolol drugs at /class/carazolol.

What development phase is Racemic Carazolol in?

Racemic Carazolol is in Phase 2.

What does Racemic Carazolol target?

Racemic Carazolol targets Beta-2 adrenergic receptor, Beta-3 adrenergic receptor, Beta-1 adrenergic receptor and is a carazolol.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing